Project Grant R43CA310344
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $303K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $609,130 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate TRIM28 inhibition as a synthetic lethal strategy for small cell lung cancers with NOTCH2-inactivation. The research will use syngeneic immunocompetent mouse models of small cell lung cancer to test whether TRIM28 inhibition restores anti-tumor immune responses in NOTCH2-mutant tumors. The work builds on prior...
- The National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $681,200 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer and test strategies to overcome that resistance. The project tests whether CD74-positive drug-tolerant persister cells drive acquired resistance to osimertinib and other third-generation EGFR tyrosine kinase inhibitors. The...
- The National Cancer Institute awarded Matrisome Bio, Inc. $3,481,203 on September 23, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer. Matrisome Bio is developing molecularly targeted drugs based on nanobodies that specifically target disease-associated extracellular matrix (ECM) proteins highly expressed in lung cancer and other cancer indications while minimally expressed in...
- The National Cancer Institute awarded the University of California, Los Angeles $540,204 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small molecule modulators targeting the RNA exonuclease polynucleotide phosphorylase (PNPASE) as a therapeutic strategy for therapy-resistant, immune-cold KRAS/LKB1 mutant non-small cell lung cancer. The award funds research into PNPASE inhibitors (MTPNPIs) that induce accumulation of cytosolic mitochondrial...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- The National Cancer Institute awarded Molecular Targeting Technologies, Inc. $637,529 on August 24, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop targeted radionuclide therapy for non-small cell lung cancer using Lu-177 EBRGD. The award funds research to evaluate in vivo tumor targeting, biodistribution, therapeutic efficacy, and normal tissue toxicity of 177Lu-DOTA-EB-RGD as a treatment for non-small cell lung cancer, which accounts for 80–85 percent...
- The National Cancer Institute awarded $400,000 to Dauntless Biotherapeutics, Inc. on August 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop CD155-targeted antibody-drug conjugates for metastatic and triple-negative breast cancer. The project advances therapeutic candidates that combine direct tumor cytotoxicity with restoration of anti-tumor immunity. CD155 is expressed in over 60% of breast cancers, including triple-negative, HER2-positive, and HER2-low...
- The National Cancer Institute awarded Northeastern University $224,400 under the Cancer Biology Research program (CFDA 93.396) on August 1, 2026, to develop a direct RNA sequencing platform that detects dihydrouridine (D) modifications in human lung cancer transcripts at transcriptome-wide, single-nucleotide resolution. Current technologies cannot reliably distinguish dihydrouridine from pseudouridine and uridine, limiting understanding of how uridine modifications regulate RNA biology in...
- The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
- The National Cancer Institute awarded the University of Massachusetts Medical School $622,611 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize CAS9 nickase as a cancer-selective genotoxic agent targeting focal gene amplification in MYCN-amplified neuroblastoma. The project, titled "Creating Cancer-Specific Genotoxicity by Targeting CAS9 Nickase to Focal Gene Amplifications," addresses an unmet medical need in MYCN-amplified...